O
TYRA icon

OrbiMed’s Tyra Biosciences TYRA Stock Holding History

OrbiMed’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Buy
+102,000
New +$3.37M 0.06% 114
2025
Q3 		– Sell
-804,603
Closed -$7.7M – 122
2025
Q2 		$7.7M Sell
804,603
-948,228
-54% -$9.01M 0.19% 68
2025
Q1 		$16.3M Buy
1,752,831
+282,745
+19% +$3.66M 0.39% 48
2024
Q4 		$20.4M Buy
1,470,086
+701,448
+91% +$12.7M 0.42% 54
2024
Q3 		$18.1M Hold
768,638
– – 0.33% 67
2024
Q2 		$12.3M Hold
768,638
– – 0.24% 69
2024
Q1 		$12.6M Buy
+768,638
New +$12.6M 0.23% 75

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

OrbiMed's TYRA Position: Q2 2026 in Review

OrbiMed opened a new position in Tyra Biosciences (TYRA) in Q2 2026: 102,000 shares worth $3.26M. The stake represents 0.06% of the portfolio and ranks #114 among its holdings. This is a return to the name: OrbiMed previously reported a position in TYRA as recently as Q2 2025.

OrbiMed first reported a position in TYRA in Q1 2024 and has held it in 7 quarters since. The position peaked at $20.4M in Q4 2024. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • OrbiMed held 102,000 shares of Tyra Biosciences worth $3.26M as of Q2 2026.
  • Tyra Biosciences was a new OrbiMed position in Q2 2026.
  • Tyra Biosciences made up 0.06% of OrbiMed's portfolio in Q2 2026, its #114 holding.
  • OrbiMed first reported a position in Tyra Biosciences in Q1 2024 and has held it in 7 quarters since.
  • OrbiMed's Tyra Biosciences position peaked at $20.4M in Q4 2024.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.